$0.54— 0.00%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
Market cap
—
P/E
—
Forward P/E
—
P/B
—
Dividend yield
—
Payout
—
EPS
-$2.94
ROE
-172.20%
Profit margin
-148.42%
Revenue growth
-31.80%
Beta
0.98
52-week high
$1.86
52-week low
$0.36
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
Equity, revenue and profitEquityRevenueNet income
findstockfast.com
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Revenue4 years
findstockfast.com
Net debtDebt minus cash — below zero means more cash than debt
findstockfast.com
Investors holding this
Major managers that reported this stock in their latest 13F.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
Indicator
Median
2025
2024
2023
2022
Year-end price
$0.93
$0.90
$2.40
$3.05
P/S
0.5x
0.4x
0.4x
0.7x
0.7x
P/B
0.3x
—
0.4x
0.3x
0.2x
EPS
-$2.66
-$6.63
-$8.67
-$10.73
Profit margin
-222.31%
-115.28%
Others in the same sector
Companies of similar size in Consumer Cyclical, for comparison. The columns are the same ones above, in the same order.
DSS, Inc. operates in the product packaging, biotechnology, commercial lending, securities and investment management, and direct marketing businesses in the United States. The company manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products. It invests in or acquires companies in the biohealth and biomedical fields, including businesses that focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune related diseases; and develops open-air defense initiatives for air-borne infectious diseases comprising tuberculosis and influenza. In addition, the company focuses on acquiring equity positions in undervalued commercial banks, bank holding companies, and nonbanking licensed financial companies; and companies engages in nonbanking activities related to banking, such as loan syndication, mortgage banking, trust and escrow, banking technology, loan servicing, equipment leasing, problem asset management, special purpose acquisition company consulting, and advisory capital raising services. Further, the company provides securities and investment management services; and operates a real estate investment trust for acquiring hospitals and other acute or post-acute care centers. Additionally, it develops and acquires assets and investments in the securities trading and funds management arena, as well as lists and operates as a digital asset on secondary market. The company was formerly known as Document Security Systems, Inc. and changed its name to DSS, Inc. in September 2021. DSS, Inc. was incorporated in 1984 and is headquartered in West Henrietta, New York.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.